Scilex (SCLX) Stock Price, News & Analysis

Company Overview

Scilex Holding Company, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of non-opioid therapies for pain management. The company’s core mission is to address unmet medical needs in patients suffering from acute and chronic pain by offering innovative topical and injectable products designed to provide targeted relief while minimizing systemic exposure.

Scilex’s lead marketed product is ZTlido, a lidocaine topical system approved for the treatment of peripheral neuropathic pain associated with post-herpetic neuralgia. In addition to ZTlido, the company’s clinical pipeline features novel formulations such as a dexamethasone gel intended for epidural administration following spinal surgery and exploratory programs targeting neuropathic pain and osteoarthritis. These products leverage proprietary drug-delivery technologies aimed at enhancing efficacy and convenience for patients.

Formed through a strategic combination of development-stage assets in the early 2020s, Scilex is headquartered in Southern California and conducts commercial and clinical activities across the United States. The company works with a network of specialty distributors, wholesalers and direct-to-physician sales channels to ensure broad access to its therapies. Scilex also collaborates with contract research organizations and manufacturing partners to support its ongoing research and development efforts.

The executive leadership team at Scilex brings together seasoned professionals with extensive backgrounds in pharmaceutical research, regulatory affairs and global commercialization. Under their guidance, the company continues to pursue strategic partnerships and licensing opportunities to expand its portfolio of non-opioid pain treatments. Looking ahead, Scilex aims to build on its existing product suite while advancing late-stage programs toward regulatory approval and market launch.

Key Stats

• Today's Range: $6.20 to $6.60
• 50-Day Range: $4.01 to $6.97
• 52-Week Range: $3.60 to $73.50
• Volume: 84,297 shs
• Average Volume: 68,303 shs
• Market Capitalization: $44.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $455.00
• Consensus Rating: Moderate Buy

Scilex Stock Analysis - MarketRank™

Scilex scored higher than 51% of companies evaluated by MarketBeat, and ranked 561st out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Scilex has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Scilex has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Scilex are expected to grow in the coming year, from ($0.57) to ($0.41) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Scilex is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Scilex is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.59% of the float of Scilex has been sold short.

Short Interest Ratio / Days to Cover

Scilex has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Scilex has recently decreased by 1.55%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Scilex does not currently pay a dividend.

Dividend Growth

Scilex does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.59% of the float of Scilex has been sold short.

Short Interest Ratio / Days to Cover

Scilex has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Scilex has recently decreased by 1.55%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Scilex has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.01 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Scilex this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for SCLX on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Scilex to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Scilex insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.94% of the stock of Scilex is held by insiders.

Percentage Held by Institutions

69.67% of the stock of Scilex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SCLX Stock Analysis - Frequently Asked Questions

How have SCLX shares performed this year?

Scilex's stock was trading at $14.9240 at the beginning of 2025. Since then, SCLX stock has decreased by 56.7% and is now trading at $6.46.

How were Scilex's earnings last quarter?

Scilex Holding Company (NASDAQ:SCLX) issued its quarterly earnings data on Friday, January, 17th. The company reported ($6.30) earnings per share (EPS) for the quarter.

When did Scilex's stock split?

Shares of Scilex reverse split on the morning of Tuesday, April 15th 2025.The 1-35 reverse split was announced on Friday, April 11th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 14th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of Scilex?

Shares of SCLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Scilex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Scilex investors own include Rigetti Computing (RGTI), Pfizer (PFE), BioNTech (BNTX), Hertz Global (HTZ), Nikola (NKLA) and BlackBerry (BB).

Company Calendar

• Last Earnings: 1/17/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SCLX
• CIK: 1820190
• Web: www.scilexholding.com
• Phone: 650-516-4310
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Scilex: $455.00
• High Price Target: $630.00
• Low Price Target: $245.00
• Potential Upside/Downside: +6,943.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($29.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$72.81 million
• Net Margins: -146.93%
• Pretax Margin: -146.94%
• Return on Equity: N/A
• Return on Assets: -82.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.10
• Quick Ratio: 0.09

Sales & Book Value

• Annual Sales: $56.59 million
• Price / Sales: 0.79
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($27.68) per share
• Price / Book: -0.23

Miscellaneous

• Outstanding Shares: 6,950,000
• Free Float: 6,400,000
• Market Cap: $44.90 million
• Optionable: Optionable
• Beta: 1.19